Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02884479 | An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study | unknown | Phase 1 / Phase 2 | 75 | SciClone Pharmaceuticals International (Cayman) Development LimitedINDUSTRY | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | unknown | Phase 1 / Phase 2 | 59 | NHS Greater Glasgow and Clyde |
| 1 |
| Mar 19, 2018 |
| clinicaltrials |
| NCT03464032 | A Study of BCD-135 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | BiocadINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT03446911 | Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery | unknown | Phase 1 / Phase 2 | 20 | Amsterdam UMC, location VUmcOTHER | 0 | Feb 27, 2018 | clinicaltrials |
| NCT02151721 | Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer(VICTORY-J) | unknown | Phase 1 | 12 | Kanazawa UniversityOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT03201146 | Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | unknown | Phase 1 / Phase 2 | 48 | West China HospitalOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03198923 | Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer | unknown | Phase 1 | 30 | Wenxiang WangOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT03282435 | Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody | unknown | Phase 1 | 30 | Dalian UniversityOTHER | 0 | Sep 14, 2017 | clinicaltrials |
| NCT03205930 | Neo-MASCT Immunotherapy for Advanced NSCLC. | unknown | Phase 1 / Phase 2 | 20 | The First People's Hospital of LianyungangOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT02441972 | Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics | unknown | Phase 1 | 200 | Wuxi No. 4 People's HospitalOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT02695550 | Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer | unknown | Phase 1 | 40 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Mar 9, 2017 | clinicaltrials |
| NCT03057340 | The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells | unknown | Phase 1 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Feb 20, 2017 | clinicaltrials |
| NCT03050411 | Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer | unknown | Phase 1 | 30 | Peking University Third HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT02274337 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02906163 | First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy | unknown | Phase 1 / Phase 2 | 188 | SciClone PharmaceuticalsINDUSTRY | 1 | Sep 19, 2016 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02876978 | Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma | unknown | Phase 1 | 20 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 24, 2016 | clinicaltrials |
| NCT02651441 | D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC) | unknown | Phase 1 / Phase 2 | 60 | Shenzhen Hornetcorn Bio-technology Company, LTDINDUSTRY | 1 | May 24, 2016 | clinicaltrials |
| NCT02737735 | The Effect on Decreasing Chemotherapeutic Toxicity and Increasing Anti-tumor Effect of Chinese Herbs Based on Syndrome Differentiation | unknown | Phase 1 | 200 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT00690963 | Individual Boosting in Non-Small Cell Lung Cancer Using Hypofractionation, Intensity-modulated Radiation Therapy and Respiratory Gating | unknown | Phase 1 / Phase 2 | 12 | AHS Cancer Control AlbertaOTHER | 1 | Apr 6, 2016 | clinicaltrials |
| NCT02691871 | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR | unknown | Phase 1 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 25, 2016 | clinicaltrials |
| NCT02688673 | DC Vaccine Combined With CIK Cells in Patients With SCLC | unknown | Phase 1 / Phase 2 | 30 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT01784107 | A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 45 | Gachon University Gil Medical CenterOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT01772732 | Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC | unknown | Phase 1 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 9, 2015 | clinicaltrials |
| NCT02066870 | Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI | unknown | Phase 1 | 9 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 13, 2015 | clinicaltrials |
| NCT01426841 | Pilot Project of Adaptive Thoracic Radiotherapy for Small Cell Lung Cancer | unknown | Phase 1 | 10 | AHS Cancer Control AlbertaOTHER | 1 | Oct 2, 2014 | clinicaltrials |
| NCT01861223 | Afatinib Plus Nimotuzumb for NSCLC | unknown | Phase 1 / Phase 2 | 50 | Samsung Medical CenterOTHER | 1 | Feb 25, 2014 | clinicaltrials |
| NCT00809237 | Hydroxychloroquine and Gefitinib to Treat Lung Cancer | unknown | Phase 1 / Phase 2 | 71 | National University Hospital, SingaporeOTHER | 1 | Dec 10, 2013 | clinicaltrials |
| NCT01027676 | Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC) | unknown | Phase 1 / Phase 2 | 50 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 14, 2013 | clinicaltrials |
| NCT01147211 | Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC) | unknown | Phase 1 | 21 | National Taiwan University HospitalOTHER | 1 | May 3, 2013 | clinicaltrials |
| NCT01203735 | Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 20 | Soroka University Medical CenterOTHER | 1 | Mar 29, 2011 | clinicaltrials |
| NCT00874328 | A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | unknown | Phase 1 / Phase 2 | 74 | National Cancer Center, KoreaOTHER_GOV | 1 | Oct 25, 2010 | clinicaltrials |
| NCT00516100 | Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC | unknown | Phase 1 / Phase 2 | 62 | Aptium Oncology Research NetworkNETWORK | 1 | Jan 15, 2010 | clinicaltrials |
| NCT00846443 | Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 | 12 | Fudan UniversityOTHER | 1 | Feb 18, 2009 | clinicaltrials |
| NCT00828022 | Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer(SMC4692) | unknown | Phase 1 / Phase 2 | 15 | Soroka University Medical CenterOTHER | 1 | Jan 23, 2009 | clinicaltrials |
| NCT00497250 | Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy | unknown | Phase 1 | 32 | Fudan UniversityOTHER | 1 | Oct 21, 2008 | clinicaltrials |
| NCT00673777 | Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 14 | Tokyo UniversityOTHER | 1 | May 14, 2008 | clinicaltrials |
| NCT00674258 | Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 14 | Tokyo UniversityOTHER | 1 | May 14, 2008 | clinicaltrials |
| NCT00379717 | Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 1 / Phase 2 | 30 | Universitair Ziekenhuis BrusselOTHER | 1 | Mar 13, 2008 | clinicaltrials |
| NCT00062907 | Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer | unknown | Phase 1 | 9 | Corixa CorporationINDUSTRY | 1 | Dec 6, 2006 | clinicaltrials |
| NCT00082472 | Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC) | unknown | Phase 1 / Phase 2 | 30 | ZivenaINDUSTRY | 1 | Apr 18, 2006 | clinicaltrials |
| NCT00040560 | Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer | unknown | Phase 1 | — | CopharosINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Apr 25, 2018source: clinicaltrials